Century Therapeutics stock extends strong run as IPSC jumps over 700 percent in 12 months

Century Therapeutics stock (ISIN US15671W1045) has delivered a striking turnaround in the past year, with the IPSC share price recently quoted around USD 1.88 and the company’s market capitalization up about 701.1 percent over the last 12 months as of September 18, 2026.

IPSC price level and 12-month performance

According to AltIndex in data updated on September 18, 2026, Century Therapeutics stock is trading near USD 1.88 per share, giving IPSC an implied market capitalization of about USD 340 million as of that date.

The same AltIndex comparison shows that IPSC’s market capitalization has increased by approximately 701.1 percent over the past 12 months, whereas the peer stock QTTB has lost 32.6 percent in that period, underscoring how sharply investor sentiment toward Century Therapeutics has improved compared with at least one smaller biotechnology peer.

Business context and fundamentals

Century Therapeutics operates in the biotechnology sector, focusing on cell-based therapies, and is classified within the broader Health Care industry in the AltIndex overview; while the latest detailed quarterly or annual revenue and earnings figures are not broken out in that comparison, the strong 12-month market-cap gain suggests that recent operational or strategic milestones have resonated with investors.

Historically, small-cap biotechnology companies such as Century Therapeutics have been sensitive to clinical trial progress and funding conditions; IPSC’s move from a substantially lower market capitalization to about USD 340 million over one year positions it more firmly among mid-range development-stage biotech names, giving the company somewhat greater financial flexibility than it had when its valuation was several times lower.

Stock positioning and investor takeaways

For investors, the key takeaway as of September 18, 2026 is that Century Therapeutics stock now trades at a relatively low absolute price near USD 1.88, but with a markedly higher implied valuation than a year ago thanks to the roughly 701.1 percent increase in market capitalization; the contrast with QTTB’s 32.6 percent market-cap decline in the same period highlights how selective the market has been in rewarding perceived progress in the biotechnology segment.

IPSC price snapshot and market context

As of the latest completed trading day referenced in the AltIndex data on September 18, 2026, Century Therapeutics stock is quoted around USD 1.88 on its primary U.S. exchange in U.S. dollars, with an implied market capitalization of about USD 340 million and a 12-month performance of approximately +701.1 percent versus the prior year’s level.

More news and analyses on Century Therapeutics stock